Tumor Metastasis: Fishing for drugs

Screening for drugs that disrupt embryonic development in zebrafish can help identify treatments that suppress metastasis.
  1. Chinyere Kemet
  2. Emily Hill
  3. Hui Feng  Is a corresponding author
  1. Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, United States
  2. Department of Medicine, Section of Hematology and Medical Oncology, Boston University School of Medicine, United States

About 90% of all cancer-related deaths are caused by metastasis, which is when cancer cells spread to other parts of the body to form new tumors (Chaffer and Weinberg, 2011; Suhail et al., 2019). Yet, the majority of currently available therapeutics do not inhibit metastasis, and only target the primary tumor where the cancer initially arises from.

To screen anti-cancer drugs, researchers often carry out experiments on mice or cells grown in the laboratory. While these model systems have led to effective treatments, they have limitations when it comes to testing drugs that block metastasis. For instance, cells cultured in the laboratory cannot accurately replicate tumor progression in humans (Katt et al., 2016), and metastasis can take at least several weeks to appear in mouse models, which are expensive to create and maintain (Simons and Brayton, 2017). Now, in eLife, Joji Nakayama, Zhiyuan Gong and co-workers report an innovative zebrafish model for screening anti-metastasis drugs (Nakayama et al., 2021).

The zebrafish was introduced to the research field in 1972, and has become a powerful model system for cancer research, due to its relative transparency, high reproduction rates, and genetic similarity to humans (Brown et al., 2017; Chen et al., 2021; Fazio et al., 2020; Gamble et al., 2021; Hason and Bartůněk, 2019). Early in development, cells in the zebrafish embryo undergo a morphological change and migrate inwards via a process called epiboly (Bruce and Heisenberg, 2020). The way these healthy cells move is similar to how cancer cells travel across tissues during metastasis. Hence, Nakayama et al. proposed that small-molecule inhibitors that interrupt epiboly may also suppress metastasis.

The team (who are based at the National University of Singapore, the National Cancer Center in Japan and other institutes in Singapore and Japan) found that some of the genes expressed during zebrafish epiboly are also activated during tumor metastasis. This finding provides the experimental support that zebrafish epiboly can serve as a model for tumor cell movement. So, Nakayama et al. developed a zebrafish screening platform, which they used to test 1,280 drugs that had already been approved by a government agency, such as the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA).

The screen was carried out on zebrafish embryos exposed to a specific drug at four hours post-fertilization (Figure 1A). Nakayama et al. found that 132 of the drugs tested induced a delay in epiboly after five hours of treatment. Several of these drugs had previously been reported to inhibit molecular mechanisms associated with metastasis (Liu et al., 2013; Nakayama et al., 2020).

New approach for screening anti-metastasis drugs.

(A) Zebrafish were bred and their embryos were collected and plated into individual wells. Each embryo was treated four hours post-fertilization (hpf) with either the vehicle (an inactive substance that the drug is mixed with to facilitate administration) or a drug that had been approved by the FDA, EMA, or another government agency for cancer treatment: two concentrations were administered (10 µm and 50 µm). Out of the 1,280 drugs tested, 132 interrupted or delayed epiboly five hours after the drug was administered. (B) 62 of these positive hits were then tested on tumor cells cultured in the laboratory. This revealed that 20 of these drugs also impeded the migration of cancer cells, in addition to disrupting epiboly in zebrafish. One of the identified drugs, called Pizotifen, was then administered to zebrafish and mice models that had been injected with fluorescently labelled human cancer cells (commonly referred to as xenografts). This showed that the drug can also suppress metastasis in vivo.

Image credit: Emily Hill; the 6-well plate is adapted from an image by DataBase Center for Life Science (DBCLS; CC BY 4.0).

Nakayama et al. then used cell-based assays to test whether 62 of these 132 ‘positive hits’ (which also delay epiboly in vitro) can suppress the migration of cancer cells (Figure 1B). The tumor cells were placed in a chamber with or without the drug, and the team recorded how many could crawl into the neighboring compartment after a few hours of treatment. This revealed that 20 of the drugs that disrupted epiboly also impeded the movement of human cancer cells.

Finally, Nakayama et al. tested if one of the epiboly-interrupting drugs called Pizotifen could also impair tumor cell movement in living animals: this drug was selected because its primary target (serotonin receptor 2C) is highly expressed in human cancer cells during metastasis. To do this, they injected fluorescently labelled cancer cells into zebrafish embryos, and found that fish exposed to Pizotifen experienced significantly less metastasis than fish treated with a placebo. Similar observations were made in mice that had cancer cells injected into their breast-like tissue, half of which were treated with a daily dose of Pizotifen, and half of which received a placebo (Figure 1B).

The screening platform created by Nakayama et al. makes it easy to rapidly find new drugs that suppress metastasis, while circumventing the limitations of cell culture and mouse model systems. In addition, zebrafish injected with human cancer cells can serve as an additional means for narrowing down which drugs to test in mouse models. Having zebrafish join the drug discovery platform will hopefully result in more and better treatments for patients with metastatic cancers.

References

  1. Book
    1. Simons BW
    2. Brayton C
    (2017) Chapter 3 - Challenges and Limitations of Mouse Xenograft Models of Cancer
    In: Simons BW, editors. Patient Derived Tumor Xenograft Models: Promise, Potential and Practice. Academic Press. pp. 25–36.
    https://doi.org/10.1016/B978-0-12-804010-2.00003-5

Article and author information

Author details

  1. Chinyere Kemet

    Chinyere Kemet is in the Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, United States

    Contributed equally with
    Emily Hill
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5471-9964
  2. Emily Hill

    Emily Hill is in the Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, United States

    Contributed equally with
    Chinyere Kemet
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5874-6209
  3. Hui Feng

    Hui Feng is the Department of Pharmacology and Experimental Therapeutics and Department of Medicine, Section of Hematology and Medical Oncology, Boston University School of Medicine, Boston, United States

    For correspondence
    huifeng@bu.edu
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1318-821X

Acknowledgements

HF acknowledges grants from the National Institutes of Health (NIH; CA215059), the American Cancer Society (RSG-17-204-01-TBG), the National Science Foundation (1911253), and Boston University; CK thanks the diversity grant support from the National Institutes of Health (NIH; CA215059S); and EH is grateful for the Undergraduate Research of Program Award from Boston University.

Publication history

  1. Version of Record published: February 8, 2022 (version 1)

Copyright

© 2022, Kemet et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 890
    Page views
  • 92
    Downloads
  • 0
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Chinyere Kemet
  2. Emily Hill
  3. Hui Feng
(2022)
Tumor Metastasis: Fishing for drugs
eLife 11:e76632.
https://doi.org/10.7554/eLife.76632

Further reading

    1. Developmental Biology
    Arun Devotta, Hugo Juraver-Geslin ... Jean-Pierre Saint-Jeannet
    Research Article Updated

    Natriuretic peptide signaling has been implicated in a broad range of physiological processes, regulating blood volume and pressure, ventricular hypertrophy, fat metabolism, and long bone growth. Here, we describe a completely novel role for natriuretic peptide signaling in the control of neural crest (NC) and cranial placode (CP) progenitors formation. Among the components of this signaling pathway, we show that natriuretic peptide receptor 3 (Npr3) plays a pivotal role by differentially regulating two developmental programs through its dual function as clearance and signaling receptor. Using a combination of MO-based knockdowns, pharmacological inhibitors and rescue assays we demonstrate that Npr3 cooperate with guanylate cyclase natriuretic peptide receptor 1 (Npr1) and natriuretic peptides (Nppa/Nppc) to regulate NC and CP formation, pointing at a broad requirement of this signaling pathway in early embryogenesis. We propose that Npr3 acts as a clearance receptor to regulate local concentrations of natriuretic peptides for optimal cGMP production through Npr1 activation, and as a signaling receptor to control cAMP levels through inhibition of adenylyl cyclase. The intracellular modulation of these second messengers therefore participates in the segregation of NC and CP cell populations.

    1. Developmental Biology
    2. Evolutionary Biology
    Joaquín Letelier, Lorena Buono ... Juan R Martínez-Morales
    Research Article

    Genetic studies in human and mice have established a dual role for Vsx genes in retina development: an early function in progenitors’ specification, and a later requirement for bipolar-cells fate determination. Despite their conserved expression patterns, it is currently unclear to which extent Vsx functions are also conserved across vertebrates, as mutant models are available only in mammals. To gain insight into vsx function in teleosts, we have generated vsx1 and vsx2 CRISPR/Cas9 double knockouts (vsxKO) in zebrafish. Our electrophysiological and histological analyses indicate severe visual impairment and bipolar cells depletion in vsxKO larvae, with retinal precursors being rerouted toward photoreceptor or Müller glia fates. Surprisingly, neural retina is properly specified and maintained in mutant embryos, which do not display microphthalmia. We show that although important cis-regulatory remodelling occurs in vsxKO retinas during early specification, this has little impact at a transcriptomic level. Our observations point to genetic redundancy as an important mechanism sustaining the integrity of the retinal specification network, and to Vsx genes regulatory weight varying substantially among vertebrate species.